STATISTICAL AND METHODOLOGICAL ISSUES IN EVALUATION OF INTEGRATED CARE PROGRAMSChenglin Ye(Wuhan University)MacSphere (McMaster University)January 1, 2014Cited by 0SaveCiteExport RISWatch citationsRelated PapersAdjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial|The Lancet Oncology|2018|216